IRIS
DE PLACIDO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.867
NA - Nord America 2.480
EU - Europa 1.990
SA - Sud America 308
Continente sconosciuto - Info sul continente non disponibili 132
AF - Africa 64
OC - Oceania 2
Totale 7.843
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.352
SG - Singapore 1.182
RU - Federazione Russa 835
CN - Cina 563
IT - Italia 549
VN - Vietnam 521
BR - Brasile 231
HK - Hong Kong 200
DE - Germania 165
FR - Francia 101
IN - India 89
NL - Olanda 84
CA - Canada 83
FI - Finlandia 69
BD - Bangladesh 68
GB - Regno Unito 61
JP - Giappone 58
KR - Corea 42
AR - Argentina 38
CI - Costa d'Avorio 27
MX - Messico 24
PK - Pakistan 19
ES - Italia 18
PH - Filippine 18
PL - Polonia 17
ZA - Sudafrica 15
IQ - Iraq 14
TH - Thailandia 12
UA - Ucraina 12
BE - Belgio 10
CZ - Repubblica Ceca 10
SE - Svezia 10
EC - Ecuador 9
ID - Indonesia 9
TR - Turchia 9
TW - Taiwan 9
VE - Venezuela 9
RS - Serbia 8
UZ - Uzbekistan 8
AT - Austria 7
JM - Giamaica 7
EG - Egitto 6
IR - Iran 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
CL - Cile 5
CR - Costa Rica 5
IE - Irlanda 5
LT - Lituania 5
CO - Colombia 4
MY - Malesia 4
PY - Paraguay 4
UY - Uruguay 4
CY - Cipro 3
GR - Grecia 3
JO - Giordania 3
KE - Kenya 3
KH - Cambogia 3
LV - Lettonia 3
NP - Nepal 3
SY - Repubblica araba siriana 3
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
DZ - Algeria 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
MN - Mongolia 2
NG - Nigeria 2
PE - Perù 2
RO - Romania 2
TN - Tunisia 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
MC - Monaco 1
MD - Moldavia 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
Totale 7.705
Salva come PNG Salva come JPEG
Città #
Singapore 617
San Jose 514
Ashburn 269
Hefei 195
Moscow 195
Hong Kong 191
Naples 160
Ho Chi Minh City 148
Beijing 147
Chandler 136
Santa Clara 111
Hanoi 104
Dallas 94
Munich 85
Los Angeles 73
New York 66
Amsterdam 65
Lauterbourg 57
Tokyo 52
The Dalles 47
Council Bluffs 46
Buffalo 34
Kochi 34
Seoul 33
Turku 31
Millbury 29
Rome 29
Milan 28
Lawrence 27
Orem 26
Da Nang 25
Toronto 25
São Paulo 24
Frankfurt am Main 23
Haiphong 23
Montreal 23
Boston 22
Pune 22
Redondo Beach 22
Lappeenranta 21
Napoli 19
Des Moines 17
Helsinki 17
Nuremberg 17
Denver 16
Brooklyn 15
Mexico City 14
Ottawa 14
Casoria 13
Poplar 13
Seattle 13
Houston 12
London 12
Belo Horizonte 11
Warsaw 11
Biên Hòa 10
Manchester 10
Shanghai 10
Wilmington 10
Atlanta 9
Chennai 9
Johannesburg 9
Turin 9
Bologna 8
Dong Ket 8
Baghdad 7
Chicago 7
Düsseldorf 7
Stockholm 7
Tashkent 7
Brno 6
Formia 6
Jacksonville 6
Kingston 6
Lahore 6
Massa di Somma 6
Ninh Bình 6
Phoenix 6
Redwood City 6
Vienna 6
Washington 6
Belgrade 5
Boardman 5
Borgomanero 5
Falkenstein 5
Hải Dương 5
Long Xuyen 5
Porto Alegre 5
Rio de Janeiro 5
Salt Lake City 5
Salvador 5
San Francisco 5
Tirana 5
Brussels 4
Bình Phước 4
Bắc Giang 4
Bến Tre 4
Cairo 4
Can Tho 4
Charlotte 4
Totale 4.368
Salva come PNG Salva come JPEG
Nome #
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 207
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial 204
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 202
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 195
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 192
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis 189
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 182
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor 175
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials 174
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 169
Prevalence of Sarcopenia in Women with Breast Cancer 162
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 162
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 161
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 161
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 160
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) 159
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 157
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 156
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 155
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 154
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 151
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 150
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 149
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 147
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 146
Mechanisms of resistance to mTOR inhibitors 145
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 145
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 144
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 141
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 140
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 138
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 136
BRAF Gene and Melanoma: Back to the Future 136
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 136
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 135
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 130
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 129
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 125
Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors 123
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie 119
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 119
Immunological signature of patients with thymic epithelial tumors and Good syndrome 119
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials 117
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 116
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 115
Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response 112
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 109
Statin use and survival in patients with metastatic castrationresistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: The international retrospective observational STABEN study 96
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a 82
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study 69
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study 65
Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention 63
Ductal Carcinoma In Situ 60
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis 60
The European Reference Network: the keystone for the management of rare thoracic cancers 54
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer 51
Management of Autoimmune Conditions Associated With Thymic Epithelial Tumors 49
Multidisciplinary approach for rare thoracic tumors during COVID-19 pandemic 43
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis 39
Circulating tumor DNA in early-stage triple-negative breast cancer: clinical landscape and key open challenges 34
Serum HDL subfractions are impaired by COVID-19 vaccine in patients with thymic epithelial tumors 18
Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study 12
Totale 7.843
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.121
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.121
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022209 0 3 11 7 2 5 11 9 7 22 70 62
2022/2023397 34 34 14 17 36 39 14 43 51 78 21 16
2023/2024407 15 53 59 39 19 57 6 50 8 5 52 44
2024/20252.026 63 69 4 54 70 134 201 132 118 230 777 174
2025/20264.458 418 307 484 375 715 259 591 226 479 292 127 185
2026/2027135 105 30 0 0 0 0 0 0 0 0 0 0
Totale 7.843